Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 13:13:1094258.
doi: 10.3389/fendo.2022.1094258. eCollection 2022.

Probiotic induced synthesis of microbiota polyamine as a nutraceutical for metabolic syndrome and obesity-related type 2 diabetes

Affiliations
Review

Probiotic induced synthesis of microbiota polyamine as a nutraceutical for metabolic syndrome and obesity-related type 2 diabetes

Tina I Bui et al. Front Endocrinol (Lausanne). .

Abstract

The gut microbiota regulates multiple facets of host metabolism and immunity through the production of signaling metabolites, such as polyamines which are small organic compounds that are essential to host cell growth and lymphocyte activation. Polyamines are most abundant in the intestinal lumen, where their synthesis by the gut microbiota is influenced by microbiome composition and host diet. Disruption of the host gut microbiome in metabolic syndrome and obesity-related type 2 diabetes (obesity/T2D) results in potential dysregulation of polyamine synthesis. A growing body of evidence suggests that restoration of the dysbiotic gut microbiota and polyamine synthesis is effective in ameliorating metabolic syndrome and strengthening the impaired immune responses of obesity/T2D. In this review, we discuss existing studies on gut microbiome determinants of polyamine synthesis, polyamine production in obesity/T2D, and evidence that demonstrates the potential of polyamines as a nutraceutical in obesity/T2D hosts.

Keywords: metabolic syndrome; nutraceutical; obesity; polyamine; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of natural polyamines in healthy adults. The three most abundant polyamines in humans are putrescine, spermidine, and spermine. Total polyamine is highest in the intestine because diet and gut microbiome are the primary sources of polyamines. From the gastrointestinal tract, polyamines are readily absorbed and enter circulation where they are found in a variety of organs including the brain, kidneys, and in metabolic fluids such as urine, and breastmilk. Studies that reported concentrations in ng/mL or μg/mL were transformed to μM using the molecular weights of putrescine (88.15 g/mol), spermidine (145.25 g/mol), and spermine (202.34 g/mol) for better comparisons.
Figure 2
Figure 2
Proposed health benefits of dietary polyamines in obesity-related diseases. Polyamines are essential to human health, with their abundance altered by obesity-related diseases. This figure highlights a summary of potential benefits of polyamines on obesity-related diseases including metabolic syndrome and type 2 diabetes. Polyamines ameliorate metabolic syndrome by reducing weight gain, insulin resistance, lipid metabolism, gut barrier function, and metabolic endotoxemia. Polyamines also regulate both innate and adaptive immunity including proinflammatory cytokine production, autophagy, macrophage polarization, T cell differentiation, and B cell senescence. Further investigation is needed to elucidate polyamine-mediated health benefits in obesity-related diseases.

Similar articles

Cited by

References

    1. Bramante CT, Lee CJ, Gudzune KA. Treatment of obesity in patients with diabetes. Diabetes Spectr Publ Am Diabetes Assoc (2017) 30:237–43. doi: 10.2337/ds17-0030 - DOI - PMC - PubMed
    1. Eckel RH, Alberti K, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet (2010) 375:181–3. doi: 10.1016/s0140-6736(09)61794-3 - DOI - PubMed
    1. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb (2005) 12:295–300. doi: 10.5551/jat.12.295 - DOI - PubMed
    1. Hossain P, Kawar B, Nahas ME. Obesity and diabetes in the developing world — a growing challenge. N Engl J Med (2007) 356:213–5. doi: 10.1056/nejmp068177 - DOI - PubMed
    1. Federation ID. IDF diabetes atlas. In: International diabetes federation, 10th edn (2021). Available at: https://www.diabetesatlas.org.

Publication types